Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Compare Drugs in Protein Kinase Inhibitors [MoA]

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now
Drug Reports Deaths Death Rate Hosp. Life-Threat. Avg Age % Female
IBRUTINIB 75,087 12,580 16.8% 24,920 1,697 71.2 yrs 39.2%
EVEROLIMUS 39,640 8,374 21.1% 11,211 1,311 53.4 yrs 60.0%
CABOZANTINIB S-MALATE 39,270 4,203 10.7% 6,193 423 65.0 yrs 29.9%
DASATINIB 30,019 2,681 8.9% 6,437 669 56.4 yrs 51.9%
ERLOTINIB 22,472 6,791 30.2% 3,693 270 67.2 yrs 59.8%
SUNITINIB MALATE 21,578 6,028 27.9% 5,720 467 64.3 yrs 35.6%
PAZOPANIB 21,208 5,612 26.5% 4,347 572 61.2 yrs 41.2%
DABRAFENIB 19,305 4,165 21.6% 5,325 500 58.3 yrs 48.0%
TRAMETINIB DIMETHYL SULFOXIDE 16,286 3,925 24.1% 3,438 267 57.8 yrs 49.1%
SIROLIMUS 11,371 1,737 15.3% 3,535 816 43.1 yrs 45.4%

Head-to-Head Comparisons

IBRUTINIB vs EVEROLIMUS IBRUTINIB vs CABOZANTINIB S-MALATE IBRUTINIB vs DASATINIB IBRUTINIB vs ERLOTINIB EVEROLIMUS vs CABOZANTINIB S-MALATE EVEROLIMUS vs DASATINIB EVEROLIMUS vs ERLOTINIB CABOZANTINIB S-MALATE vs DASATINIB CABOZANTINIB S-MALATE vs ERLOTINIB DASATINIB vs ERLOTINIB
← Back to Protein Kinase Inhibitors [MoA] Class side effects →